Koninklijke Philips N.V. (PHI1.F)
| Previous close | 24.05 |
| Open | 24.10 |
| Bid | 23.99 x 34800 |
| Ask | 24.00 x 34700 |
| Day's range | 24.10 - 24.10 |
| 52-week range | 16.15 - 28.04 |
| Volume | |
| Avg. volume | 1,957 |
| Market cap | 22.597B |
| Beta (5Y monthly) | 0.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.83 |
| Earnings date | 29 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 12 May 2022 |
| 1y target est | N/A |
- Yahoo Finance Video
Eli Lilly seeks to expand Zepbound use to treat sleep apnea
Eli Lilly (LLY) is reporting success in the use of Zepbound — one of the pharmaceutical giant's landmark GLP-1 weight-loss drugs — to treat sleep apnea. Yahoo Finance Health Reporter Anjalee Khemlani joins The Morning Brief to discuss Eli Lilly's filing for approval from the US Food and Drug Administration (FDA) for this use case and how it may affect makers of CPAP (Continuous Positive Airway Pressure) sleep devices, such as Philips (PHG) and ResMed (RMD). For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.
GlobeNewswirePhilips completes cancellation of 4.4 million shares
June 19, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA) today announced that it has completed the cancellation of 4,437,164 of its shares. The cancelled shares were acquired as part of the completed EUR 1.5 billion share repurchase program for capital reduction purposes that was announced on July 26, 2021. Philips’ current issued share capital amounts to EUR 187,987,876.80 representing 939,939,384 common shares. More information is available here. For further information,
ZacksPhilips' (PHG) Diagnosis & Treatment Segment Drives Growth
Philips (PHG) boosts Diagnosis & Treatment on the back of Precision Diagnosis and Image-Guided Therapy businesses and an expanding partner base.
